Skip to main content
Clinical Trials/EUCTR2010-020979-23-IT
EUCTR2010-020979-23-IT
Active, Not Recruiting
N/A

Randomized fase II study using chemiotherapy with metformine in patients affected by pancreas metastatic cancer. - ND

FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR0 sitesJuly 16, 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
pancreas metastatic tumor
Sponsor
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
Status
Active, Not Recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 16, 2010
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR

Eligibility Criteria

Inclusion Criteria

  • \-cytologic and istologic diagnosis of pancreatic adenocarcinoma; \-presence of metasatasis; \-absebce of crebral metastasis with symptoms; \-age between 18\-75 yeras old (71\-75 only if KPS\>70%); \-Karnofsky PS \> 60 ; \-measurable disease; \-GB \> 3500/mm3, neutrofili \> 1500/mm3; Plt \> 100000/mm3; Hb \> 10 g/dl; \-creatinine \< 1\.5 mg/dL; bilirubine \< 2 mg/dL; SGOT e SGPT \< 3 UNL; \-written informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \-previous metformine assumption; \-previous or concomitant malignant tumors, apart from carcinoma in sito of the uterine cervix and epitelial malignant tumors adeguately treated or other malignant tumors if patiet was free from pathology from almost 5 years ; \-pregnancy and breast feeding; \-counter\-indications for chemiotherapic treatment (acute heart attack 4 months before the study enrollment, heart failure; \-alcool abuse;

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS LymphomaCentral Nervous System Lymphoma
DRKS00003763niversitätsklinikum Freiburg, Abt. Med 1, Hämatologie/ Onkologie227
Active, Not Recruiting
N/A
A Randomized Phase II Study of two chemotherapy regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxane Pretreated Advanced Breast Cancer Patients - NDWomen with histologic or cytologic diagnosis of advanced breast cancer, who have received one prior chemotherapy containing anthracyclines as neo adjuvant or palliative 1st-line treatment and one prior chemotherapy containing taxanes as neo adjuvant or palliative 1st-line treatment.MedDRA version: 8.1Level: LLTClassification code 10055113Term: Breast cancer metastatic
EUCTR2006-000441-19-ITELI LILLY160
Active, Not Recruiting
N/A
Randomised phase II trial on primary chemotherapy with high-dose Methotrexate and high-dose Cytarabine with or without Thiotepa, and with or without Rituximab, followed by brain irradiation vs high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed Primary CNS Lymphoma. - IELSG 32
EUCTR2009-012432-32-GBniversity Hospital Southampton NHS Foundation Trust126
Active, Not Recruiting
N/A
Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. high-dose chemotherapy supported by autologous stem cells transplantation for immunocompetent patients with newly diagnosed primary cns lymphoma. - IELSG 32newly diagnosed primary CNS lymphoma in immunocompetent patientsMedDRA version: 9.1Level: LLTClassification code 10036685
EUCTR2009-012432-32-ITIELSG-International Extranodal Lymphoma Study Group126
Active, Not Recruiting
N/A
Et randomiseret fase ll studie af primær kemoterapi med højdosis Methotrexat oghøjdosis Cytarabin med eller uden thiotepa og med eller uden Rituximab efterfulgtaf strålebehandling eller højdosis kemoterapi med autolog stamcelletransplantationhos immunkompetente patienter med nydiagnosticeret primært CNS-lymfom.ewly diagnosed Primary CNS LymphomaTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2009-012432-32-DKInternational Extranodal Lymphoma Srudy Group IELSG126